You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Large

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced DLBCL, Extra-nodal Involvement, Large Mass, Radiotherapy Trial (6-8 cycles (21 days per cycle) of Standard R-CHOP

Not yet recruiting
  • Advanced Diffuse Large B-Cell Lymphoma
  • +2 more
  • 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy
  • Radiotherapy beyond standard R-CHOP Chemotherapy
  • (no location specified)
May 24, 2023

Diffuse Large B Cell Lymphoma | DLBCL Recurrent/Refractory Trial (ZR2-ICE)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent/Refractory
  • (no location specified)
Sep 5, 2023

High-Dose Methotrexate Clearance in Diffuse Large B-Cell

Recruiting
  • Central Nervous System Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Non-Interventional Study
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Sep 8, 2023

Recurrent DLBCL, Refractory Diffuse Large B-cell Lymphoma Trial in Tianjin (RC19D2 cell injection)

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-cell Lymphoma
  • RC19D2 cell injection
  • Tianjin, Tianjin, China
    Hematology Hospital of the Chinese Academy of Medical Sciences
Sep 14, 2023

Communication Training Intervention for Large B-Cell Lymphoma

Recruiting
  • Lymphoma, B-Cell
  • +5 more
  • Hematolo-GIST Training
  • Participants Appointment
  • New York, New York
  • +2 more
Jul 3, 2023

Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory Trial in Hangzhou (Anlotinib HCl, Rituximab,

Recruiting
  • Diffuse Large B-cell Lymphoma Recurrent
  • Diffuse Large B Cell Lymphoma Refractory
  • Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Oct 12, 2023

Relapsed or Refractory Diffuse Large B-cell Lymphoma Trial in Beijing (BEBT-908 for injection)

Active, not recruiting
  • Relapsed or Refractory Diffuse Large B-cell Lymphoma
  • BEBT-908 for injection
  • Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Oct 8, 2023

DLBCL Trial (Polatuzumab Vedotin)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • Polatuzumab Vedotin
  • (no location specified)
Jul 12, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab vedotin and Rituximab)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Zanubrutinib, Polatuzumab vedotin and Rituximab
  • Shanghai, Shanghai, China
    Zhongshan Hospital，Fudan University
Jul 10, 2023

Coronary Artery Disease Trial in Jining (SeQuent® Please drug coating balloon(DCB),Firehawk family drug eluting stent(DES))

Recruiting
  • Coronary Artery Disease
  • SeQuent® Please drug coating balloon(DCB)，Firehawk family drug eluting stent(DES)
  • Jining, Shandong, China
    Jining Medical University Affiliated Hospital
Jul 23, 2023

Large Hole Percutaneous Arterial Closure Trial (PerQseal ELITE)

Not yet recruiting
  • Large Hole Percutaneous Arterial Closure
  • PerQseal ELITE
  • (no location specified)
Jul 10, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab Vedotin, Rituximab)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Zanubrutinib, Polatuzumab Vedotin, Rituximab
  • Shanghai, Shanghai, China
    Zhongshan Hospital，Fudan University
Jul 10, 2023

Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral Trial (SGN-35T)

Not yet recruiting
  • Lymphoma, T-Cell, Cutaneous
  • +5 more
  • (no location specified)
Nov 2, 2023

Circular RNAs in ALKpositive Anaplastic Large-cell Lymphoma

Active, not recruiting
  • ALK-Positive Anaplastic Large Cell Lymphoma
  • RNAseq
  • Toulouse, France
    IUCT-Oncopole University Hospital
Jul 3, 2023

Selinexor Combined With Lenalidomide and Rituximab in Treatment

Not yet recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • Selinexor combined with lenalidomide and rituximab
  • Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
Jun 20, 2023

Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Cyclophosphamide)

Not yet recruiting
  • Diffuse Large B-cell Lymphoma
  • (no location specified)
Mar 9, 2023

DLBCL Trial in Jinan (Mitoxantrone Hydrochloride Liposome Injection)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • Mitoxantrone Hydrochloride Liposome Injection
  • Jinan, Shandong, China
    Affiliated Cancer Hospital of Shandong First Medical University
May 16, 2023

Diffuse Large B Cell Lymphoma Trial in Rouen (Measure of the circulating tumor DNA)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • Measure of the circulating tumor DNA
  • Rouen, France
    Centre Henri Becquerel
Nov 17, 2023

Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma:

Completed
  • Diffuse Large B-cell Lymphoma
    • East Hanover, New Jersey
      Novartis
    Jun 16, 2023

    Large Cell Neuroendocrine Carcinoma of the Lung Trial in Athens (Atezolizumab, Carboplatin, Etoposide)

    Completed
    • Large Cell Neuroendocrine Carcinoma of the Lung
    • Athens, Greece
    • +1 more
    Sep 16, 2023

    Large B-cell Lymphoma Trial (Glofitamab, Polatuzumab vedotin, Obinutuzumab)

    Not yet recruiting
    • Large B-cell Lymphoma
    • (no location specified)
    Oct 3, 2023

    Relapsed/Refractory Large B-cell Lymphoma Trial (KITE-197, Cyclophosphamide, Fludarabine)

    Not yet recruiting
    • Relapsed/Refractory Large B-cell Lymphoma
    • (no location specified)
    Oct 6, 2023

    Primary Mediastinal Large B-cell Lymphoma With CNS Involvement

    Recruiting
    • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
      • Milan, Italy
        Ospedale San Raffaele
      Aug 29, 2023

      DLBCL Trial (Acalabrutinib, Rituximab)

      Not yet recruiting
      • Diffuse Large B-Cell Lymphoma
      • (no location specified)
      Jul 11, 2023

      Large B-cell Lymphoma, DLBCL, Not Otherwise Specified, Primary Mediastinal Large B-cell Lymphoma (PMBCL) Trial (Epcoritamab)

      Available
      • Large B-cell Lymphoma
      • +4 more
      • Epcoritamab
      • (no location specified)
      Feb 16, 2023